PurposeSpirituality is a core component of holistic cancer care, yet additional support is needed to understand and implement spirituality-focused interventions in practice. The aim of this review was to identify available interventions to address spirituality among people with cancer, to explore common components, and to examine efficacy across intervention...
BackgroundPreliminary evidence suggests psilocybin may have therapeutic value for various mental health conditions; despite this, it is currently illegal in the UK. Less is known about how people form their attitudes towards psilocybin policies.ObjectivesTo explore whether beliefs about the benefits and safety of psilocybin influence support for psilocybin p...
In the 1950s-60s, serotonergic psychedelic drugs were studied as potential adjuvants to psychotherapy to treat addiction and alcoholism. However, starting in the 70s, preclinical and clinical studies on psychedelics stopped for decades because legislation controlled its recreational use, citing their hallucinogenic and psychotomimetic effects, as well as the...
Unknown journal2025-07-31Adebo M, Bonnet M, Laouej O, Defaix C, McGowan JC, Butlen-Ducuing F, David DJ, Poupon E, Tritschler L, Gardier AM.
Europe PMCPublishedpsilocybinpsilocinDepressionAnxietyAddictionNeuroplasticityPharmacologyMechanism of ActionReceptor PharmacologyClinical TrialReview ArticleAnimal StudyClinical TrialAnimalsHumans
Psychedelic treatment with psilocybin is receiving increased attention following clinical trials showing it may help treat end-of-life anxiety, depression, and several other conditions. Despite this, physicians may be reluctant to prescribe psilocybin and carry out psilocybin treatment because of the stigma surrounding psychedelics and the potential for medi...
This article describes the Swiss limited access program for psychedelic/3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy. The Swiss Federal Office of Public Health can issue authorizations for the limited medical use of otherwise prohibited substances. To be eligible, patients suffer from a mostly incurable disease, the prohibited substance can alle...
Psilocybin, a psychedelic compound in "magic" mushrooms, has promise as a novel treatment for psychiatric disorders, many of which are more prevalent in females and have onsets during adolescence. However, there is a lack of research about how factors such as sex and age affect responses to psilocybin, as well as potential safety concerns with developmental ...
